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Abstract Deregulation of the HER2 oncogene occurs in 30% of
human breast cancers and correlates with poor prognosis and
increased propensity for metastasis. Since the molecular basis of
HER2 overexpression in human cancers is not known, we sought
to determine whether chromatin remodeling pathways are
involved in the regulation of HER2 expression. We report that
compared with breast cancer cells expressing a low level of
HER2, HER2-overexpressing breast cancer cells contained
significantly higher levels of acetylated and phosphorylated
histone H3, and acetylated histone H4 associated with the HER2
promoter. Decreased recruitment of histone deacetylases in the
promoter is also noted in the HER2-overexpressing cell. The
association of acetylated histone H4 with HER2 gene chromatin
and HER2 expression in breast cancer cells was upregulated by
an inhibitor of histone deacetylases. Treatment with histone
deacetylase inhibitor also reduced the association of histone
deacetylase-1 and -2 with the HER2 promoter. In addition, the
tumor promoters 12-O-tetradecanoylphorbol-13-acetate and
okadaic acid stimulated the association of phosphorylated
histone H3 on serine 10 with the HER2 promoter and also
stimulated HER2 expression. These findings identify histone
acetylation and histone phosphorylation as novel regulatory
modifications that target HER2 gene chromatin, and suggest
that elevated levels of these chromatin-relaxing components in
the vicinity of the HER2 gene promoter may constitute an
important non-genomic mechanism of HER2 overexpression in
human breast cancer. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
Growth factors and their receptors play an essential role in
the regulation of mammary epithelial cell proliferation. Ab-
normalities in the expression and action of receptor tyrosine
kinases contribute to the progression and maintenance of the
malignant phenotype in breast cancer [1]. For example, the
human epidermal growth factor receptor 2 (HER2) has been
found to be overexpressed in 20^30% of breast tumors, and is
frequently associated with an aggressive clinical course, short
disease-free survival periods, poor prognosis, and higher pro-
pensity for metastasis in human breast cancer [2]. Overexpres-
sion of HER2 in transgenic mice has been shown to cause
breast tumors [3]. Conversely, downregulation of HER2 in-
hibits the transformed phenotype in cancer cells and leads to
growth inhibition [4^6]. In spite of the widely acknowledged
role of HER2 overexpression in breast cancer, the mechanism
of HER2 overexpression in breast cancer remains elusive.
Following the discovery of HER2 protein upregulation in
human cancer, it was generally believed that HER2 gene am-
pli¢cation was the cause of HER2 overexpression in cancer
cells. However, a number of studies using human breast can-
cer cell lines have repeatedly demonstrated a role of enhanced
transcription in upregulating the net expression of HER2
mRNA per gene copy [7^9]. This stimulated transcription is
presumably due to elevated activity of the transcription fac-
tors with consensus sites in the HER2 promoter. In fact, over
the years, several transcription factors, including AP-2, PEA3,
RBP-Jk, and HTF, have been shown to enhance transcription
from the HER2 promoter [10^14] and hence, have been im-
plicated in the process of HER2 overexpression in cancer cells.
The eukaryotic genome is compacted with histone and oth-
er proteins to form chromatin, which consists of repeating
units of nucleosomes [15]. For transcription factors to access
DNA, the repressive chromatin structure needs to be remod-
eled. Dynamic alterations in the chromatin structure can fa-
cilitate or suppress access of transcription factors to nucleo-
somal DNA, leading to transcription regulation. One way to
achieve dynamic alterations in chromatin structures is through
alterations in the acetylation or phosphorylation states or
both of nucleosomal histones [15,16]. Acetylation of core his-
tones occurs at lysine residues on the amino-terminal tails of
the histones, thus neutralizing the positive charge of the his-
tone tails and decreasing their a⁄nity for DNA. Hyperacety-
lated chromatin is generally associated with transcriptional
activation, whereas hypoacetylated chromatin is associated
with transcriptional repression [17^19]. The acetylation state
of histones is regulated by a dynamic interaction between
recently identi¢ed groups of enzymes known as histone ace-
tyltransferases and histone deacetylases (HDACs) [19]. In ad-
dition to acetylation, another mechanism that can result in the
unfolding of chromatin is phosphorylation of histone H3
[20,21]. In brief, acetylation and phosphorylation constitute
important links between chromatin structure and transcrip-
tion outcome.
Despite the widely acknowledged role of enhanced tran-
scription in HER2 overexpression, the molecular mechanism
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by which HER2 gene chromatin a¡ects the level of HER2
transcript and the potential role of chromatin remodeling
pathways in the non-genomic overexpression of HER2 in
breast cancer cells remains unexplored. Here we explored
the hypothesis that histone acetylation and histone phosphor-
ylation regulate HER2 promoter chromatin and, conse-
quently, expression of HER2 transcript in breast cancer cells.
We provide new evidence that elevated levels of chromatin-
relaxing components in the vicinity of the HER2 gene pro-
moter may be responsible for HER2 overexpression in human
breast cancer.
2. Materials and methods
2.1. Cell cultures and reagents
Human breast cancer cells were cultured in the recommended media
supplemented with 10% fetal bovine serum. Antibodies against acety-
lated H3 and acetylated H4 and trichostatin A (TSA) were purchased
from Upstate Biotechnology. The anti-acetylated H3 antibody recog-
nizes K9 and K14 [22^24]. The anti-acetylated H4 antibody recognizes
tetra-acetylated H4 with high a⁄nity [25,26]. Antibody against phos-
phorylated histone H3 at serine 10 was from Cell Signaling Technol-
ogy. Antibodies against HER2, HDAC1 and HDAC2 were from
Santa Cruz. Phorbol 12-myristate 13-acetate and okadaic acid were
purchased from Gibco BRL.
2.2. Cell extracts and immunoblotting
For preparation of cell extracts, cells were washed three times with
phosphate-bu¡ered saline and lysed in bu¡er (50 mM Tris^HCl, pH
7.5: 120 mM NaCl; 0.5% Nonidet P-40; 100 mM NaF; 200 mM
NaVO5, 1 mM phenylmethylsulfonyl £uoride; 10 Wg/ml leupeptin;
10 Wg/ml aprotinin) for 15 min on ice. The lysates were centrifuged
in an Eppendorf centrifuge at 4‡C for 15 min. Cell lysates containing
equal amounts of protein were resolved on 7% SDS^polyacrylamide
gel, transferred to nitrocellulose, and probed with appropriate anti-
bodies.
2.3. Chromatin immunoprecipitation (ChIP) assay
Approximately 106 cells were treated with 1% formaldehyde (¢nal
concentration, v/v) for 10 min at 37‡C to cross-link histones to DNA.
The cells were washed twice with phosphate-bu¡ered saline, pH 7.4
containing protease inhibitor cocktail (Boehringer Mannheim). The
ChIP assay was performed as described [27,28]. The sequences of
the primers used in this study are described in Table 1.
2.4. RT-PCR analysis and HER2 promoter^reporter assays
The sequences of the HER2 primers are described in Table 1. Sin-
gle-step RT-PCR reaction was carried out in a 50 Wl reaction, fol-
lowed by 35 cycles of 1 min at 94‡C, 1 min at 55‡C, and 1 min at 72‡C
and a ¢nal cycle of 7 min at 72‡C. The RT-PCR product was resolved
onto a 1% agarose gel [29]. The HER2 PCR product was 910 bp.
The HER2 promoter^luciferase activity was determined as de-
scribed after transiently transfecting with pNeulit [30], which contains
the HER2 promoter fused with a reporter luciferase gene [12].
3. Results and discussion
3.1. Acetylated histones interact with the HER2 promoter in
breast cancer cells
To investigate the potential role of chromatin-remodeling components in the overexpression of HER2 in human breast
cancer, we did ChIP assays to examine the acetylated histone
H3 and H4 associated with the HER2 promoter. We deter-
mined the baseline acetylation status of histone H3 and H4
around the PEA3 site in the HER2 promoter. The signi¢cance
of the PEA3 site in the HER2 promoter was established by
mutating the PEA3 site [12], which abolishes the HER2 pro-
moter activity, ¢ve-fold in a reporter-based system (data not
shown). For these initial studies, we used a series of well-
characterized breast cancer cell lines with low (such as
Table 1
Primer pairs 5P-3P forward/reverse Name
AACACATCCCCCTCCTTGACTATC ChIP for HER2
AGCTTCACTTTCTCCCTCTCTTCG
CGCGAAGAGAGGGAGAAAGTGA ChIP for pNeulit
CGATATGTGCATCTGTAAAAGCAATT
TTGGACAGCACCTTCTACCG HER2 for RT-PCR
GCAGGAGTTACGTTCTCTGG
Fig. 1. Acetylation of the HER2 promoter chromatin in HER2-
overexpressing breast cancer cells. A: Western blot analysis of
HER2 protein expression in breast cancer cell lines. B, C: Associa-
tion of HER2 promoter with acetylated histone H3 and histone H4.
Chromatin lysates were immunoprecipitated with antibodies against
acetylated histone H3 (B) and acetylated histone H4 (C), and sam-
ples were processed as described in Section 2. The upper panels
show the PCR analysis of the 313 bp HER2 DNA fragment associ-
ated with acetylated histone H3 or acetylated histone H4. The 1%
input DNA is shown in the lower panels. Results are presented as
quantitation of fold change of acetylated H3/H4-associated HER2/
DNA signal with reference to equal input DNA.
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MCF-7 cells) or high HER2 content due to gene ampli¢cation
(SKBR-3 and BT-474 cells [8]) or increased transcription (ZR-
75R, MDA-175, and BT-483 cells [8]). Compared with MCF-
7 cells, HER2-overexpressing breast cancer cells exhibited sig-
ni¢cantly higher levels of both acetylated histone H3 (Fig. 1B)
and acetylated histone H4 (Fig. 1C) associated with the HER2
promoter. The observation that the extent of histone H3 acet-
ylation of the HER2 promoter was similar in cells without
HER2 gene ampli¢cation (such as ZR-75R cells) and cells
with HER2 ampli¢cation (such as SKBR3) suggested that
the observed association of acetylated histones with the
HER2 promoter in cells with high HER2 expression might
be independent of the status of HER2 gene ampli¢cation.
These observations suggested the possibility of preferential
targeting of HER2 promoter chromatin by histone acetylation
components.
3.2. HDAC inhibitor stimulates association of acetylated
histones H3 and H4 with the HER2 promoter
To examine the role of chromatin remodeling via histone
acetylation in HER2 expression, we next evaluated the e¡ect
of the HDAC inhibitor TSA on the levels of the HER2 pro-
moter-associated acetylated histones. As shown in Fig. 2A,
there was no e¡ect of TSA on the amount of HER2 promoter
interaction with the acetylated histone H3. However, TSA
treatment (8 h, 132 nM) resulted in a signi¢cant enhancement
of HER2 promoter association with the acetylated histone H4
in several breast cancer cell lines, with a maximum stimulation
of this association in the MCF-7 cell line (Fig. 2A). As there is
no signi¢cant e¡ect of 8 h treatment of MCF-7 cells with 132
nM TSA on the cell cycle analysis by FACScan (Fig. 2C), the
observed modulating e¡ect of TSA on the HER2 gene chro-
matin was not a consequence of cell cycle e¡ects of TSA.
Fig. 2. Stimulation of HER2 gene chromatin interaction with the acetylated histone H4 by HDAC inhibitor. A: MCF-7, ZR-75R and SKBR-3
breast cancer cells were treated with 132 nM TSA for 8 h. Chromatin lysates from control and TSA-treated cells were immunoprecipitated
with anti-acetylated histone H3 or anti-acetylated histone antibodies. Levels of the HER2 promoter associated with acetylated histone H3 and
histone H4 are shown. B: Cell cycle distribution of control and TSA-treated (132 nM for 8 h) MCF-7 cells. C: Association of HDAC1 and
HDAC2 with HER2 promoter chromatin and e¡ect of TSA. Inhibition of HER2 gene chromatin interaction with HDACs by HDAC inhibitor.
Chromatin lysates from MCF-7 (treated with or without 132 nM TSA for 8 h) and ZR-75R breast cancer cells were immunoprecipitated with
anti-HDAC1 and -HDAC2 antibodies, and levels of associated HER2 promoter are shown. D: E¡ect of TSA treatment (132 nM for 8 h) on
the expression of HDAC1 and HDAC2 in MCF-7 cells.
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3.3. TSA promotes dissociation of HDAC1 and HDAC2 from
the HER2 promoter
Because TSA promotes histone acetylation by inhibiting
HDACs and because HDACs have been shown to interact
with the target gene chromatin [31], we explored whether
HDACs are recruited around the PEA3 site in the HER2
promoter and if such interactions are a¡ected by TSA. As
shown in Fig. 2C, more HDAC1 and HDAC2 are found in
MCF-7 cells than in ZR-75 cells. Treatment of MCF-7 cells
with TSA resulted in decreased physical interaction of
HDAC1 and HDAC2 with the endogenous HER2 promoter
(Fig. 2C). There was no e¡ect of TSA treatment on the ex-
pression of HDAC1 and HDAC2 in MCF-7 cells (Fig. 2D).
3.4. HDAC inhibitor stimulates HER2 expression
Since hyperacetylation of target gene chromatin is known
to be generally associated with increased transcription [18], we
examined the ability of TSA to upregulate HER2 promoter
activity using a HER2^luciferase reporter construct contain-
ing the HER2 promoter [12,30]. Inhibition of HDAC activity
by TSA stimulated the HER2 promoter-driven transcription
from the reporter system (Fig. 3A). To test whether the tran-
siently expressed HER2 template is assembled as chromatin,
we used a modi¢ed ChIP method. MCF-7 cells transfected
with HER2^luciferase plasmid were treated with or without
TSA. Histone-associated DNA fragments were immunopreci-
pitated with antibodies against acetylated histone H3 or H4,
and ampli¢ed by PCR using primers speci¢c for HER2^lucif-
erase (Table 1). As shown in Fig. 3B, transfected HER2^lu-
ciferase plasmid was assembled as chromatin and TSA en-
hanced the association of acetylated histone H4 but not
histone H3 with the transiently expressed HER2 template.
This observation is consistent with the ¢nding that TSA af-
fects the levels of acetylated histone H4 associated with the
endogenous HER2 promoter (Fig. 2A).
Next we determined the e¡ect of TSA on HER2 expression
Fig. 3. Stimulation of HER2 expression by HDAC inhibitor. A: E¡ect of TSA on HER2 promoter^luciferase in MCF-7 cells. B: E¡ect of
TSA treatment (132 nM for 8 h) on the association of acetylated histone H3 and histone H4 with the HER2 promoter adjacent to transiently
expressed luciferase gene in MCF-7 cells. Input for acetylated histone H3 and acetylated histone H4 ChIP analysis is the same. C: MCF-7 and
ZR-75R cells were treated with 132 nM of TSA for 8 h and the levels of HER2 and GAPDH mRNA were assayed by RT-PCR. D: MCF-7
and ZR-75R cells were treated with 132 nM of TSA for 8 h and the levels of HER2 and vinculin proteins were assayed by Western blotting.
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in MCF-7 cells (low HER2 content) and ZR-75R cells (high
HER2 content without gene ampli¢cation). Treatment of cells
with TSA (132 nM, 8 h) was accompanied by a signi¢cant
upregulation of HER2 mRNA in the both cell lines (Fig. 3C).
We further noticed that TSA-mediated increased transcription
of HER2 promoter leads to an increased HER2 expression as
compared to the HER2 level in untreated control cells (Fig.
3D).
The expression of only 2% of cellular genes has been shown
to be modulated by histone acetylation [19]. Our results have
identi¢ed the HER2 gene as one of the targets of chromatin
remodeling agents such as TSA. Since TSA preferentially in-
Fig. 4. Remodeling of HER2 promoter chromatin by phosphorylation of histone H3 on serine 10 by TPA. A: ChIP analysis of baseline associ-
ation of HER2 promoter with phosphorylated histone H3. B: Chromatin lysates from control and TPA-treated (10 nM for 12 h) MCF-7 cells
were immunoprecipitated with anti-phospho-histone H3 antibody. The levels of associated HER2 promoter with phosphorylated histone H3 are
shown. C: E¡ect of TPA treatment (10 nM for 12 h) on the levels of HER2 promoter^luciferase in MCF-7 cells. D: E¡ect of 16 h TPA (10^
100 nM) treatment on the levels of HER2 and GAPDH mRNA by RT-PCR assay. E: Remodeling of HER2 promoter chromatin by phos-
phorylation of histone H3 on serine 10 by okadaic acid and e¡ect of TSA (132 nM) on phospho/acetylated H3 association with HER2 pro-
moter. Chromatin lysates from control and okadaic acid-treated (0.5 WM okadaic acid for 12 h) cells were immunoprecipitated with anti-phos-
pho histone H3 antibody. The levels of associated HER2 promoter are shown. F: E¡ect of okadaic acid treatment (0.5 WM for 12 h) on the
levels of HER2 and GAPDH mRNA by RT-PCR assay. G: ChIP analysis of baseline association of phospho-acetylated histone H3 with
HER2 promoter in MCF-7 and BT-474 cell lines and the e¡ect of TSA on it in MCF-7 cells. Chromatin lysates from control and TSA-treated
(132 nM for 8 h) cells were immunoprecipitated with anti-acetyl-phospho-histone H3 antibody. The levels of associated HER2 promoter are
shown.
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duced the status of histone H4 acetylation and its association
with the HER2 promoter chromatin and since TSA activated
HER2 expression, these observations suggest that the acetyla-
tion of histone H4 in the vicinity of HER2 promoter chroma-
tin was regulated by HDACs and that histone H4 hyperacet-
ylation remodels chromatin in favor of enhanced transcription
activity.
3.5. HER2 promoter chromatin remodeling by phosphorylation
of histone H3 on serine 10
In addition to acetylation, the second major modi¢cation
responsible for chromatin relaxation is phosphorylation of
histone H3 on serine 10 [20,21]. To explore the potential in-
volvement of histone H3 phosphorylation in HER2 overex-
pression in breast cancer cells, we examined the level of HER2
promoter associated with histone H3 in MCF-7 cells (low
HER2 content), ZR-75R cells (HER2 overexpression without
gene ampli¢cation), and BT-474 cells (HER2 overexpression
due to gene ampli¢cation). Compared with MCF-7 cells, both
types of HER2-overexpressing breast cancer cells exhibited a
signi¢cant elevation in the amount of HER2 promoter asso-
ciated with the phosphorylated histone H3 (Fig. 4A). This
¢nding indicates that association of HER2 gene promoter
with phosphorylated histone H3 is independent of HER2
gene ampli¢cation status. Recent studies have shown that tu-
mor promoters such as phorbol ester 12-O-tetradecanoylphor-
bol-13-acetate (TPA), which acts through protein kinases, reg-
ulate cellular mitogenic responses via a common early
nucleosomal response leading to chromatin conformational
changes due to histone H3 phosphorylation on serine 10
[20]. Because it is not yet fully resolved whether non-genomic
pathways can trigger HER2 overexpression and the process of
cellular transformation, and because distinct extracellular sig-
nal such as TPA have been shown to contribute to tumori-
genesis, we explored whether tumor promoters could in£uence
HER2 promoter chromatin and HER2 expression in breast
cancer cells. TPA treatment of MCF-7 cells resulted in an
increase in HER2 promoter association with phosphorylated
histone H3 (Fig. 4B), activation of HER2 promoter-driven
transcription (Fig. 4C), and stimulation of HER2 transcrip-
tion (Fig. 4D).
Since the process of transformation is also known to be
a¡ected by okadaic acid, an inhibitor of serine/threonine pro-
tein phosphatase [21], we next examined the e¡ect of okadaic
acid on interaction of phosphorylated histone H3 with HER2
promoter and expression. As illustrated in Fig. 4E, okadaic
acid also promoted the interaction of HER2 promoter with
phosphorylated histone H3, and stimulated HER2 expression
(Fig. 4F). Together, these studies led to the notion that his-
tone H3 phosphorylation may constitute an additional mech-
anism of HER2 overexpression. Several recent reports have
suggested that histone phosphorylation in conjunction with
histone acetylation may potentiate gene activation [21], prob-
ably by initially loosening the chromatin. In this context we
further analyzed the baseline association of acetylated and
phosphorylated histone H3 (Lys9Ser10) in the HER2 pro-
moter in MCF-7 and BT474 cells. We found an enhanced
association of acetylated and phosphorylated histone H3
with HER2 promoter in BT-474 (high HER2 level) relative
to MCF-7 cells (Fig. 4G).
In summary, we found that (1) breast cancer cells with high
HER2 expression exhibited an increased association of acety-
lated histones H3 and H4 with the HER2 promoter, com-
pared with the cells with low HER2 expression; (2) associa-
tion of acetylated histones with the HER2 promoter in high-
HER2-expressing breast cancer cells was not dependent of the
status of HER2 gene ampli¢cation; (3) the promoter is also a
target for di¡erential HDAC recruitment and is critically im-
portant for H4 acetylation status which in turn in£uences
HER2 expression; (4) in high-HER2-expressing breast cancer
cells, HER2 promoter chromatin is also remodeled by phos-
phorylation of histone H3 on serine 10; and (5) tumor pro-
moters stimulate the association of serine 10-phosphorylated
histone H3 with HER2 promoter and stimulate expression of
HER2. These ¢ndings identify histone acetylation and histone
phosphorylation as novel regulatory modi¢cations that target
the HER2 gene in chromatin and suggest that elevated levels
of these chromatin-relaxing components in the vicinity of the
HER2 gene promoter may constitute an important non-ge-
nomic mechanism for HER2 overexpression in human breast
cancer.
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